SCHEMBL231737

SCHEMBL231737

CC(C)(C(=O)NO)N(CCC(=O)O)S(=O)(=O)c1ccc(Oc2ccc(F)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 12/20 0.55
MMP13 P45452 13/20 0.55
MMP2 P08253 11/20 0.55
MMP9 P14780 4/20 0.55
LTA4H P09960 1/20 0.49
MEP1B Q16820 1/20 0.45
FFAR1 O14842 1/20 0.44
MMP8 P22894 4/20 0.43
MMP14 P50281 3/20 0.43
MMP16 P51512 2/20 0.43
MMP3 P08254 2/20 0.41
ADAM17 P78536 1/20 0.41
NR3C1 P04150 1/20 0.41
MMP7 P09237 1/20 0.40
MMP12 P39900 1/20 0.40
ALDH1A1 P00352 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3921655 0.90 MMP2 (0.47) MMP1MMP13MMP2MMP9MEP1B
SCHEMBL7344819 0.90 MMP1 (0.43) MMP1MMP13MMP2MMP9MEP1B
SCHEMBL6817940 0.89 MMP1 (0.48) MMP1MMP13MMP2MMP9MEP1B
SCHEMBL6809658 0.89 MMP13 (0.50) MMP1MMP13MMP2MMP9LTA4H
SCHEMBL13898736 0.81 BMP1 (0.48) MMP1MMP13MMP2MMP9MEP1B
SCHEMBL6685331 0.81 MMP1 (0.48) MMP1MMP13MMP2MMP9LTA4H
SCHEMBL7344377 0.80 SMN1; SMN2 (0.48) MMP1MMP13MMP2MMP9MEP1B
SCHEMBL6813468 0.78 MMP1 (0.44) MMP1MMP13MMP2MMP9MMP8
SCHEMBL8456469 0.78 MMP9 (0.50) MMP1MMP13MMP2MMP9MMP8
SCHEMBL4618781 0.78 MMP13 (0.55) MMP1MMP13MMP2MMP9FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 573 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1003720-B1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER PROD INC (US) 2004-03-31 EP claimed
US-6417229-B1 ENZYME INHIBITORS PFIZER INC 2002-07-09 US claimed
US-6214872-B1 ANTIARTHRITIC AND ANTICARCINOGENIC AGENTS PFIZER INC. 2001-04-10 US claimed
EP-1088550-A1 alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders Pfizer Products Inc. (US) 2001-04-04 EP claimed
EP-1003720-A1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES Pfizer Products Inc. (US) 2000-05-31 EP claimed
WO-1999007675-A1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER PRODUCTS INC. (US) 1999-02-18 WO claimed
US-20250214963-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2025-07-03 US disclosed
US-12037404-B2 Human monoclonal antibodies against EphA4 and their use THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2024-07-16 US disclosed
EP-2534153-B2 SALTS AND POLYMORPHS OF 8-FLUORO-2-{4-[(METHYLAMINO}METHYL]PHENYL}-1,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3-CD]INDOL-6-ONE PFIZER (US) 2024-05-22 EP disclosed
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2024-04-04 US disclosed
EP-4166558-A1 SALTS AND POLYMORPHS OF 8-FLUORO-2-{4- [(METHYLAMINO)METHYL]PHENYL}-1 ,3,4,5-TETRAHYDRO-6H-AZEPINO[5,4,3- CD]INDOL-6-ONE Pfizer Inc. (US) 2023-04-19 EP disclosed
US-20220251066-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER INC. 2022-08-11 US disclosed
EP-3473271-B1 HUMAN MONOCLONAL ANTIBODIES AGAINST EPHA4 AND THEIR USE US GOV HEALTH & HUMAN SERVICES (US) 2022-07-20 EP disclosed
WO-2001040217-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS PFIZER PRODUCTS INC. (US) 2001-06-07 WO disclosed
WO-2001034574-A1 STABLE POLYMORPH OF N-(3-ETHYNYLPHENYLAMINO)-6,7-BIS(2-METHOXYETHOXY)-4-QUINAZOLINAMINE HYDROCHLORIDE, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF OSI PHARMACEUTICALS, INC. (US) 2001-05-17 WO disclosed
US-6214872-B1 ANTIARTHRITIC AND ANTICARCINOGENIC AGENTS PFIZER INC. 2001-04-10 US disclosed
EP-1088550-A1 alpha-sulfonylamino hydroxamic acid inhibitors of matrix metallo-proteinases for the treatment of peripheral or central nervous system disorders Pfizer Products Inc. (US) 2001-04-04 EP disclosed
WO-2000047574-A1 HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER PRODUCTS INC. (US) 2000-08-17 WO disclosed
EP-1003720-A1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES Pfizer Products Inc. (US) 2000-05-31 EP disclosed
WO-1999007675-A1 ARYLOXYARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES PFIZER PRODUCTS INC. (US) 1999-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214963-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR MMP1 3955/4885MMP13 4604/4885MMP2 4086/4885
US-20240109862-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR MMP1 3955/4885MMP13 4604/4885MMP2 4086/4885
US-20220251066-A1 SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH GPR119, INSR, LYAR MMP1 3955/4885MMP13 4604/4885MMP2 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.